 |
 |
|
Lancashire and South Cumbria
Formulary |
| Formulary Chapter 6: Endocrine system - Full Section
|
| Useful Links |
 LSCMMG: Trans Female Gender Dysphoria Information Sheet |
|
LSCMMG: Trans Male Gender Dysphoria Information Sheet |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
06.01 |
Drugs used in diabetes
(0,0)
|
|
06.01.01 |
Insulins
(0,0)
|
|
06.01.01.01 |
Short-acting insulins
(2,0)
|
|
|
Rapid Acting Insulin Analogues
(6,0)
|
|
|
Short-acting human insulin analogues
(0,0)
|
|
|
Biphasic insulins
(4,0)
|
|
|
Intermediate Acting Insulin
(2,0)
|
|
|
Long Acting Insulin Analogues
(6,0)
|
|
06.01.01.03 |
Hypodermic equipment
(2,0)
|
|
06.01.02 |
Antidiabetic drugs
(0,0)
|
|
06.01.02.01 |
Sulfonylurea
(4,0)
|
|
06.01.02.02 |
Biguanides
(1,0)
|
|
06.01.02.03 |
Other antidiabetic drugs
(1,0)
|
|
|
DPP-4 inhibitors
(0,0)
|
|
|
GLP-1 mimetics
(0,0)
|
|
|
DPP4 inhibitors (gliptins)
(6,0)
|
|
|
SGLT2 inhibitors
(5,0)
|
|
|
GLP1 agonists
(9,0)
|
|
|
Meglitinides
(0,0)
|
|
|
SGL2 inhibitors
(0,0)
|
|
|
Intestinal alpha glucosidase inhibitor
(1,0)
|
|
|
Thiazolidinediones
(2,0)
|
|
06.01.03 |
Diabetic ketoacidosis
(0,0)
|
|
06.01.04 |
Treatment of hypoglycaemia
(3,0)
|
|
|
Chronic hypoglycaemia
(1,0)
|
|
06.01.05 |
Treatment of diabetic nephropathy and neuropathy
(0,0)
|
|
|
Diabetic nephropathy
(1,0)
|
|
|
Diabetic neuropathy
(0,0)
|
|
06.01.06 |
Diagnostic and monitoring agents for diabetes mellitus
(1,0)
|
|
06.02 |
Thyroid and Antithyroid drugs
(0,0)
|
|
06.02.01 |
Thyroid hormones
(5,0)
|
|
06.02.02 |
Antithyroid drugs
(4,0)
|
|
06.03 |
Corticosteroids
(0,0)
|
|
06.03.01 |
Replacement therapy
(1,0)
|
|
06.03.02 |
Glucocorticoid therapy
(12,0)
|
|
|
Disadvantages of corticosteroids
(0,0)
|
|
|
Use of corticosteroids
(0,0)
|
|
|
Pregnancy and breastfeeding
(0,0)
|
|
|
Administration
(0,0)
|
|
|
Withdrawal of corticosteroids
(0,0)
|
|
06.04 |
Sex hormones
(0,0)
|
|
06.04.01.01 |
Oestrogens and HRT
(9,0)
|
|
|
Ethinylestradiol
(1,0)
|
|
|
Raloxifene
(1,0)
|
|
|
Oestrogens
(2,0)
|
|
06.04.01.02 |
Progestogens
(6,0)
|
|
06.04.02 |
Male sex hormones and antagonists
(2,0)
|
|
|
Anti-androgens
(3,0)
|
|
|
Dutasteride and finasteride
(0,0)
|
|
|
Growth hormone receptor antagonists
(1,0)
|
|
|
Hypothalmic hormones and protirelin
(1,0)
|
|
06.05.01 |
Hypothalamic and anterior pituitary hormones and anti-oestrogens
(1,0)
|
|
|
Anti-oestrogens
(1,0)
|
|
|
Anterior pituitary hormones
(5,0)
|
|
06.05.02 |
Posterior pituitary hormones and antagonists
(0,0)
|
|
|
Posterior pituitary hormones
(3,0)
|
|
|
Antidiuretic hormone antagonists
(2,0)
|
|
06.06 |
Drugs affecting bone metabolism
(0,0)
|
|
|
Osteoporosis
(0,0)
|
|
06.06.01 |
Calcitonin and parathyroid hormone
(4,0)
|
|
06.06.02 |
Bisphosphonates and other drugs affecting bone metabolism
(2,0)
|
|
|
Bisphosphonates
(9,0)
|
|
|
Denosumab
(2,0)
|
|
|
Strontium renelate
(1,0)
|
|
06.07 |
Other endocrine drugs
(4,0)
|
|
06.07.01 |
Bromocriptine and other dopaminergic drugs
(3,0)
|
|
06.07.02 |
Drugs affecting gonadotrophins
(2,0)
|
|
|
Gonadorelin analogues
(3,0)
|
|
|
Breast pain (mastalgia)
(0,0)
|
|
|
|
